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Abstract
TGF-b family members play a relevant role in tumorigenic processes, including hepatocellular carcinoma (HCC), but a
specific implication of the Bone Morphogenetic Protein (BMP) subfamily is still unknown. Although originally isolated from
fetal liver, little is known about BMP9, a BMP family member, and its role in liver physiology and pathology. Our results show
that BMP9 promotes growth in HCC cells, but not in immortalized human hepatocytes. In the liver cancer cell line HepG2,
BMP9 triggers Smad1,5,8 phosphorylation and inhibitor of DNA binding 1 (Id1) expression up- regulation. Importantly, by
using chemical inhibitors, ligand trap and gene silencing approaches we demonstrate that HepG2 cells autocrinely produce
BMP9 that supports their proliferation and anchorage independent growth. Additionally, our data reveal that in HepG2 cells
BMP9 triggers cell cycle progression, and strikingly, completely abolishes the increase in the percentage of apoptotic cells
induced by long-term incubation in low serum. Collectively, our data unveil a dual role for BMP9, both promoting a
proliferative response and exerting a remarkable anti-apoptotic function in HepG2 cells, which result in a robust BMP9 effect
on liver cancer cell growth. Finally, we show that BMP9 expression is increased in 40% of human HCC tissues compared with
normal human liver as revealed by immunohistochemistry analysis, suggesting that BMP9 signaling may be relevant during
hepatocarcinogenesis in vivo. Our findings provide new clues for a better understanding of BMPs contribution, and in
particular BMP9, in HCC pathogenesis that may result in the development of effective and targeted therapeutic
interventions.
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Introduction
Aberrant Transforming Growth Factor–beta (TGF-b) signaling
has been associated with many human diseases, including cancer
[1]. During the tumorigenic process, TGF-b acts as a double edge-
sword: on one hand, in normal and pre-malignant cells, TGF-b is
a cytostatic, pro-apoptotic factor. On the other hand, in cancer
cells, TGF-b promotes tumor growth, immune evasion and a
migratory/invasive phenotype. What roles other TGF-b super-
family members, such as the Bone Morphogenetic Protein (BMP)
subfamily play in cancer, has only been started to be addressed in
the past few years.
BMPs were discovered about 50 years ago for their capacity to
regulate bone and cartilage formation [2,3], but our current
knowledge indicates BMPs have a much broader role than
originally thought [4]. In fact, their relevant function during
development is beyond any reasonable doubt [5], and in recent
years, it has become clear that BMPs also play a significant role in
adult tissue homeostasis by controlling many different cellular
processes such as proliferation, differentiation, migration, survival
and apoptosis [4,6]. BMPs exert their effects by binding to a
heterotetrameric transmembrane receptor complex formed by a
type I (Activin like kinase, ALK) and a type II serine/threonine
kinase receptor that once activated recruits and phosphorylates the
specific effector proteins, so-called R-Smads, Smad1, 5 and 8.
Phosphorylated Smad1,5,8 bind to co-Smad Smad4 and accumu-
late in the nucleus, where together with specific binding partners
modulate gene transcription [7]. It has been described that BMPs
could also trigger non-canonical or non-Smad signaling pathways
that in certain contexts are key for the biological effects of BMPs
[8].
Dysregulation of BMP signaling can have pathological conse-
quences in many different diseases [9]. Among them, BMP
contribution in cancer is a matter of intense investigation as both
pro- and anti-tumorigenic activities for different members of the
family have been reported [10,11,12]. BMP ligands are overex-
pressed in several tumor types, including prostate, melanoma,
non-small cell lung carcinoma, ovarian and gastric cancer [12].
Besides, aberrant expression of BMP receptors has been associated
with the tumorigenic process [11]. Pro-tumorigenic activity of the
BMPs not only includes promotion of proliferation, migration/
invasion, epithelial to mesenchymal transition (EMT) and survival,
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but recently their role in tumor dormancy and recurrence has
been described [13].
Hepatocelullar carcinoma (HCC) is a devastating cancer type,
ranking sixth in incidence and the third leading cause of cancer
death worldwide, yet molecular mechanisms driving hepatocar-
cinogenesis remain largely unknown [14]. In fact, the role of BMPs
in HCC has only began to be addressed [15]. Aplying the systems
biology approach, in hepatitis B virus X antigen transgenic mouse,
BMP7 and BMP4 have been found to be up-regulated in cirrhosis
and liver cancer [16]. Furthermore, BMP4 and BMP6 are
overexpressed in both human HCC cell lines and tissues and
importantly, BMP4 expression strongly correlates with high tumor
grade [17,18] having recently being proposed as marker for the
prediction of HCC recurrence and prognosis [19]. BMP4
produced by HCC cells has an autocrine effect promoting
invasion and anchorage independent growth, together with a
paracrine effect increasing tube formation in endothelial cells, thus
promoting tumor vasculogenesis. BMP antagonists, Noggin and
Chordin, which are capable of sequestering BMP ligands in the
extracellular space, impaired HCC cell migration and invasion
confirming the BMP signaling involvement in these cellular
processes [20]. BMP9 was first isolated in fetal mouse liver [21],
and it is also expressed in adult healthy liver [22]. Although it is
known to be overexpressed in Hep3B and PLC/PRF/5 HCC cells
[20], its precise contribution to the hepatocarcinogenesis process
has just began to be explored. In a recent work, Li and coworkers
have found that BMP9 induces EMT and increased migration in
HCC cells [23]. Here, we have investigated BMP9 role in HCC
cell growth. Our results provide solid evidence for a role of BMP9
in the promotion of HCC cell growth, effect that was not observed
in non-transformed hepatocytes. In HepG2 cells, we demonstrated
that BMP9 promotes survival and both anchorage dependent and
independent cell growth. Importantly, using different approaches
we also show that HepG2 cells presented an autocrine BMP9
production that might occur also in vivo. Altogether, our findings
provide new clues for a better understanding of BMP contribution
in HCC pathogenesis.
Materials and Methods
1. Materials
The following reagents were used: BMP9 and ALK1 extracel-
lular domain (ALK1ecd) were from R&D Systems (Minneapolis,
MN). Dorsomorphin was from Calbiochem (La Joya, CA) and
LDN193189 from Miltenyi Biotec (Pozuelo de Alarco´n, Madrid).
AccuMax tissue microarrays of liver cancer tissues (A204II) and
ovary cancer tissues (A213II) were purchased from Stretton
Scientific Ltd. Bronchial Epithelial Cell Growth Medium (BEBM)
and BEGM bullet kit were purchased from Lonza Iberica
(Barcelona, Spain). Dulbecco’s modified Eagle’s medium
(DMEM), Minimum Essential Medium (MEM), fetal bovine
serum (FBS) and trypsin-EDTA were from Gibco-Invitrogen
(Barcelona, Spain). Penicillin, streptomycin, HEPES, bovine
serum albumin (fraction V, fatty-acid free), propidium iodide
and all buffer reagents were from Sigma-Aldrich. [3H]-thymidine
(25.0 Ci/mmol), Horseradish peroxidase-conjugated secondary
antibodies and ECL reagent, were from GE Healthcare Europe
(Barcelona, Spain). Antibodies against the following proteins were
used: Phospho-Smad1 (Ser463/465)/Smad5 (Ser463/465)/
Smad8 (Ser426/428) polyclonal antibody (#9511) and Smad1
polyclonal antibody (#9743) from Cell Signaling Technology
(Beverly, MA). Smad2/3 monoclonal antibody (#610842) was
from BD Biosciences (Madrid, Spain) and Inhibitor of DNA
binding1 (Id1) (C-20) polyclonal antibody (sc-488) from Santa
Cruz Biotechnology, Inc. (Paso Robles, CA). All of them were used
1:1000. Polyclonal anti human BMP9 antibody (AP2064a,
Abgent, San Diego, CA) was used in immunohistochemical
analysis.
2. Cell Culture
HepG2, Hep3B and Huh7 human HCC epithelial cells were
obtained from the European Collection of Cell Cultures
(ECACC), and non-tumoral human hepatocyte cell line THLE3
from the American Type Culture Collection (ATCC). For cell
culture, the following media were used: DMEM for HepG2 and
Huh7, MEM for Hep3B and BEBM supplemented with BEGM
Bullet kit for THLE3. THLE3 cells were cultured in coated plates
(0.01 mg/ml fibronectin, 0.03 mg/ml collagen I and 0.01 mg/ml
BSA). HepG2 cells stably expressing a reporter plasmid consisting
of BMP-responsive elements from the Id1 promoter fused to a
luciferase reporter gene (HepG2BRA) were kindly provided by Dr.
Rifkin, from New York University Langone School of Medicine
[24]. HepG2BRA cells were cultured in DMEM supplemented
with 700 mg/ml G418. Cell lines were grown in media supple-
mented with 10% FBS, 100 U of penicillin and streptomycin per
ml and maintained in a humidified incubator at 37uC and a 5%
CO2 atmosphere.
3. Proliferation Studies
10,000 or 20,000 cells/well in 12 well plates were plated and
serum starved prior to treatment with different factors. At various
time points, cells were harvested by trypsinization and cell number
was determined using a Casy cell counter (Roche).
4. DNA Synthesis Analysis
Cells were plated at a density of 17,500 cells/sq cm in DMEM
with 10% FBS. The following day, cells were serum starved and
incubated for 48 hours with or without BMP9. Incorporation of
[3H]-thymidine during the last 40 hours of culture was measured
in trichloroacetic acid-precipitable material as previously de-
scribed [25].
5. Analysis of Cell DNA Content by Flow Cytometry
Cells were harvested by trypsinization, fixed in 70% ethanol
(220uC) for 1 min, and treated with RNaseA (10 mg/ml) for
30 min at 37uC. After propidium iodide staining (0.05 mg/ml,
15 min at room temperature in the dark), the cellular DNA
content was analyzed in a FACScan flow cytometer (Becton-
Dickinson, San Jose, CA). For computer analysis, only signals from
single cells were considered (10,000 cells/assay).
6. Analysis of Apoptosis by Phosphatidylserine Exposure
Cells were harvested by trypsinization and washed once with
PBS. 500,000 cells were resuspended with 195 ml of binding buffer
(10 mM HEPES, pH 7.4, 2.5 mM CaCl2, 140 mM NaCl)
supplemented with 5 ml annexin V-FITC (BD Pharmingen) and
incubated for 10 min at room temperature. Samples were
centrifuged and resuspended with 300 ml of binding buffer
containing 1 mg/ml propidium iodide. Fluorescence intensity
was analyzed using a FACSCalibur flow cytometer. 10,000 cells
were recorded in each analysis.
7. Measurement of Apoptotic Index
Measurement of apoptotic index was performed as previously
described [26]. After staining with propidium iodide, cells
undergoing apoptosis were scored under inverted fluorescence
microscope (Eclipse TE300, Nikon) at high magnification (x60)
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following standard morphological criteria. Apoptotic indices were
calculated after counting a minimum of 1000 cells per treatment in
a blinded manner.
8. Western Blotting
Whole cell lysates and western blotting was performed as
described previously [27].
9. RNA Isolation and qRT-PCR
RNA was isolated using TRIZOL reagent (Invitrogen). cDNA
was prepared using the DyNAmo Sybr Green 2-step qRT-PCR kit
(Finnzymes). Quantitative RT-PCR was performed as described
[27]. Id1, BMP9 and 18S primers were obtained from Qiagen.
Amplified products were analyzed by a Chromo4 continuous
fluorescence detector (Biorad) and Opticon Monitor3 software.
10. Transcriptional Reporter Assay
20,000 HepG2BRA cells were plated in 24 well plates
containing DMEM plus 10% FBS and allowed to attach for 18
hours. Cells were incubated with DMEM 0.1% FBS for 8 hours
and BMP9 added. After 15 hours of treatment, cells were washed
with PBS and lysed using 100 ml of reporter lysis buffer (Promega,
Madison, USA). To measure luciferase activity, 40 ml of lysate
were added to 40 ml Luciferase Assay Reagent (Promega) and
luminescence was quantitated using a Fluostar Omega luminom-
eter (RMG Labtech). Luciferase units were normalized per cell
number.
11. Soft Agar Assays
Soft agar assays were performed as previously described [28].
Briefly, 20,000 cells/well in 6 well plates were plated in DMEM
supplemented with 5% FBS and 0.45% agarose on the top of
solidified agarose (0.9% in DMEM supplemented with 5% FBS).
300 ml DMEM with or without the treatment were added to each
well twice weekly. Colonies were counted 3 weeks after seeding.
Colonies of more than 50 mm in diameter were scored.
12. Retroviral Infection
Oligonucleotides targeting human BMP9 or non-silencing
oligos (Table S1 in File S1) were annealed and cloned into Xho-
1/Eco-RI digested MSCV/LTRmiR30-PIGDRI (LMP) (a kind gift
of Ross Dickins and Scott Lowe). All constructs were sequenced
prior to use and are referred to as non-silencing (LMP-NS), LMP-
shBMP9#1 and LMP-shBMP9#2. Retrovirus was generated as
described [27]. Stable cell pools were generated after outgrowth in
media containing 0.5 mg/ml puromycin.
13. Immunohistochemistry
Immunohistochemistry with BMP9 antibody was performed as
previously described [27].
14. Statistical Analysis
Statistical analysis was performed by Student’s t-test analysis.
Results
1. BMP9 Promotes Cell Growth in HCC Cell Lines but not
in Non-transformed Hepatocytes
Previous reports in the literature have indicated that BMP9 is
expressed mainly in fetal [21] and adult [22,29] liver where it was
shown to bind membrane receptors in non-parenchymal cells,
particularly liver endothelial cells and Kupffer cells [29]. The
HCC cell line HepG2 was also shown to respond to BMP9 with an
increased proliferation [30]. In order to extend these observations,
we first analyzed the response to BMP9 in terms of cell growth of
different liver cancer cell lines. The effect of BMP9 was checked in
low serum conditions (0.1% FBS) to avoid the bioactive
concentrations of BMPs (BMP4, BMP6 and importantly, BMP9)
in FBS [31]. Therefore, HepG2, Hep3B and Huh-7 human HCC
cells were incubated for 15 hours in 0.1% FBS media and then
treated with 5 ng/ml of BMP9 for 4 days. BMP9 triggered a
moderate but significant growth stimulatory effect in Huh7 and
Hep3B cells, while HepG2 cell number was doubled upon BMP9
treatment (figure 1A). Importantly, when non transformed
hepatocytes, such as primary adult mouse hepatocytes, immortal-
ized mouse neonatal hepatocytes or a human immortalized
hepatocyte cell line (THLE3) were treated with BMP9 in the
same conditions, the proliferative effect of BMP9 was not
observed, and even a decrease in cell number was found in
primary hepatocytes (figure 1A and figure S1 in File S1). To
further confirm these data, THLE3 cells were incubated with
different BMP9 concentrations and yet again, cell numbers were
similar in all conditions, whilst cells did respond to proliferative
stimulus like 10% FBS (figure 1B). We next assayed BMP9
treatment for different periods of time, in the presence of 10% FBS
or in low serum conditions (0.1% FBS), and THLE3 cells did not
respond to BMP9 in terms of growth in any of the conditions
tested (figure 1C). As HepG2 cells presented the best response to
BMP9-induced cell growth, we decided to use them for subsequent
experiments. In order to further optimize, if possible, our
experimental settings, we next performed a dose/response analysis
of the growth effect in HepG2 cells using two different approaches,
cell counting and the CellTiter-Glo luminescent cell viability assay.
BMP9 increased cell number in a dose-dependent manner, having
a maximal response at concentration of 5 ng/ml that was used
hereafter (figure 1D and figure S2A in File S1). Additionally, we
performed a time-course analysis of the BMP9 growth effect at
different time points. After 2 days of treatment, a significant
difference in cell number between non-treated and treated cells
was found, which was greater after longer treatment (4 to 8 days),
with a 2- to 4-fold increase in the number of cells (figure 1E and
figure S2B in File S1). To know the relevance of the BMP9 growth
effect in HepG2 cells, we compared it with other well-known liver
mitogens such as EGF, insulin and IGF1. Our data revealed that
BMP9-promoted HepG2 cell growth was comparable to that
observed with insulin, IGF1 and EGF at their respective optimal
concentrations (figure S3 in File S1). All together these data
suggest that BMP9 promotes cell growth of liver cancer cell lines,
an effect that is not observed in non-transformed hepatocytes.
2. BMP9 Activates the Canonical Pathway in HepG2 Cells
We next wanted to analyze the signaling pathway triggered by
BMP9 in HepG2 cells. BMP9 induced Smad1,5,8 phosphorylation
in a dose-dependent manner (figure 2A). Phosphorylation of
Smad1,5,8 occurred early, being already observed after 10–15
minutes of BMP9 treatment, and it was sustained for over at least
24 hours (figure 2B). To test the transcriptional response to BMP9,
we used HepG2 cells stably expressing a reporter construct
consisting of a BMP-responsive element (BRE) from the Id1
promoter fused to a luciferase reporter gene, named as
HepG2BRA cells [24]. These cells have been previously shown
to respond to several BMPs including BMP2, BMP4, BMP6 and
BMP7 by increasing the luciferase activity [24]. Here, HepG2-
BRA cells were challenged with different concentrations of BMP9
and the induction of luciferase expression was analyzed. Data
presented in figure 2C show that BMP9 treatment increased BRE-
luciferase reporter activity in a dose-dependent manner with a
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maximal stimulation at a concentration of 5 ng/ml. Consistent
with these results, we found that BMP9 enhanced Id1 expression,
both at mRNA and protein levels (figure 2D and 2B, respectively).
Jointly, these data indicate that BMP9 triggers the canonical
Smad1,5,8 pathway in HepG2 cells.
3. Autocrine BMP9 Production Supports Anchorage
Dependent and Independent HepG2 Cell Growth
While studying the growth stimulatory effects of BMP9, we
found that HepG2 cells were capable of proliferating in low serum
(0.1% FBS) conditions (figure 1E and figure S2B in File S1). These
Figure 1. BMP9 increases cell number of HCC cell lines but not of immortalized human hepatocytes. A. Huh7, Hep3B and HepG2 liver
cancer cells and immortalized human hepatocytes (THLE3) were incubated in the absence or in the presence of 5 ng/ml BMP9 in 0.1% FBS media and
counted at day 4. Data from 3 independent experiments performed in triplicate (mean 6 S.E.M.) are shown. B. THLE3 cells were incubated with
different concentrations of BMP9 in 0.1% FBS media and counted after 4 days of treatment. Data from 3 independent experiments performed in
triplicate (mean 6 S.E.M.) are shown. C. Proliferation curve of THLE3 cells incubated for different periods of time 2/+ BMP9 (5 ng/ml) in 0.1% FBS or
in 10% FBS media. Data from one representative experiment (n = 3) out of 3 (mean 6 S.D.) are shown. D. HepG2 cells were incubated with different
concentrations of BMP9 in 0.1% FBS media and counted after 4 days of treatment. Data from 3 independent experiments performed in triplicate
(mean 6 S.E.M.). E. HepG2 cells were incubated for different periods of time 2/+ BMP9 (5 ng/ml) in 0.1% FBS media. Data from 6 independent
experiments performed in triplicate (mean 6 S.E.M.). Statistical analysis was carried out using the paired t-test and data were compared to untreated
samples, * = P,0.05, ** = P,0. 01, *** = P,0.001.
doi:10.1371/journal.pone.0069535.g001
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findings, together with the fact that human transformed and non-
transformed hepatocytes express BMP9 [20,22], prompted us to
speculate on a potential autocrine BMP9 effect in HepG2 cells.
We first assayed BMP9 production in HepG2 cells by using a
previously published sensitive bioassay for BMP9 [31], and we
found that bioactive BMP9 is secreted by HepG2 cells into the
culture media (data not shown). In a next step, we took advantage
of the BMP inhibitors and ligand traps that have become available
in recent years. Dorsomorphin (Dm) was discovered in a high
throughput small molecule screen in zebrafish embryos as an
inhibitor of the BMP type I receptors, i.e. ALK2, 3 and 6 [32].
LDN193189 is a BMP inhibitor that was developed using Dm as
template and that has been described to be more potent and
specific than Dm [33]. Both Dm (1 mM) and LDN193189
(100 nM) completely blocked phosphorylation of Smad1,5,8
triggered by BMP9 in HepG2 cells (figures 3A and 3B). In these
conditions, Dm and LDN193189 effectively impaired BMP9-
induced HepG2 cell growth (figures 3D and 3E). We then tested a
purified Fc-coupled extracellular domain of ALK1 (ALK1ecd),
which binds to BMP9 with high affinity [34], and has been used
before as a specific ligand trap for BMP9 [27,35,36]. Incubation
with ALK1ecd efficiently inhibited both BMP9-induced
Smad1,5,8 phosphorylation and increase in HepG2 cell number,
demonstrating that ALK1ecd acts as a potent inhibitor for BMP9
(figures 3C and 3F). Interestingly, we also observed that ALK1ecd
treatment of Huh7, Hep3B and HepG2 cells growing in presence
of 10% FBS resulted in reduced proliferation rates in these cell
lines, suggesting that serum-derived BMP9 functions as a
proliferative factor for them (figure S4 in File S1). On the other
hand, THLE3 cell growth was not altered when ALK1ecd was
added, further confirming that normal hepatocytes do not respond
to BMP9 by increasing their proliferation (figure S4 in File S1).
When HepG2 cells were incubated in low serum media and in the
presence of either Dm or LDN193189 or importantly, ALK1ecd,
we found a decrease in basal cell proliferation (figure 3G), data
that may imply that autocrine BMPs, and specifically BMP9,
contribute to basal HepG2 cell growth. Strikingly, when THLE3
were incubated in low serum media, cell number was not modified
regardless the presence of ALK1ecd, suggesting that non-
transformed hepatocytes do not respond to a putative autocrine
BMP9 loop in terms of proliferation (figure 3H). To further
confirm these data, we performed stable knockdown experiments:
a non-silencing control (LMP-NS) and BMP9 shRNA pMir-based
retroviral vectors (LMP-shBMP9#1 and #2) were used to
generate stable HepG2 cell lines with reduced BMP9 levels
(figure 4A). shBMP9 #1 and #2 HepG2 cell lines showed an
impaired basal proliferation in 0.1% FBS media when compared
to non-silencing control cells (LMP-NS) (figure 4B). Importantly,
recombinant BMP9 was able to rescue this effect and triggered a
strong growth response in cells expressing low levels of endogenous
BMP9 (figure 4B). In agreement with these data, transient
knockdown of BMP9 using siRNA yielded a 30% decrease in
Figure 2. BMP9 activates the Smad1,5,8 pathway in HepG2 cells. A. HepG2 cells were incubated for 1 hour with different concentrations of
BMP9 in 0.1% FBS media. Western blots were performed with antibodies that recognized activated (phosphorylated) Smad1, 5 and 8 (P-Smad1,5,8)
and Smad1 as loading control. A representative experiment of 2 is shown. B. HepG2 cells were incubated for different periods of time 2/+ BMP9
(5 ng/ml) in 0.1% FBS media. Western blots were performed with antibodies that recognize Id1, P-Smad1,5,8 and total Smad1 (loading control). A
representative experiment of 3 is shown. C. HepG2 stably expressing BRE-luciferase (HepG2-BRA) cells were plated and incubated with 0.1% FBS for
15 hours, and then treated with different concentrations of BMP9 for additional 15 hours. Luciferase activity was normalized to cell number. Data are
shown as fold induction (relative to untreated cells) and are from one representative experiment (n = 4) out of 3 performed (mean 6 S.D.). Statistical
analysis was carried out using the paired t-test and data were compared to untreated samples, *** = P,0.001. D. HepG2 cells were incubated 2/+
BMP9 (5 ng/ml) for different periods of time in 0.1% FBS media and Id1 levels were analyzed by qRT-PCR and normalized to 18S. Fold changes relative
to untreated samples were determined (mean 6 S.E.M, n = 3).
doi:10.1371/journal.pone.0069535.g002
Protumorigenic Role of BMP9 in HCC Cells
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69535
HepG2 cell number when cultured in low serum. Exogenously
added BMP9 had a marked growth effect in these cells,
highlighting once again a relevant role for BMP9 in HepG2
proliferation (figure S5 in File S1).
Since BMP signaling has been previously involved in anchorage
independent growth in cancer cells including HCC cells [17], we
next aimed to analyze the potential involvement of BMP9 in this
process. In order to do so, colony formation assays were performed
in HepG2 cells treated with BMP9. An increase in the number of
colonies was observed upon BMP9 treatment when compared
with the control condition (figure 4C). Conversely, when
dorsomorphin (Dm) was assayed, we found a reduction in the
number of colonies in Dm-treated cells as compared with non-
treated cells (figure 4C). Furthermore, previously generated
shBMP9 #1 and #2 stable HepG2 cell lines grown in anchorage
independent conditions gave rise to a significantly reduced colony
number compared with control (LMP-NS) cells (figure 4D). Taken
together, these findings indicate that HepG2 cells exhibit an
autocrine BMP9 signaling, which supports their growth, both in
anchorage dependent and independent conditions.
Figure 3. Effect of BMP receptor inhibitors and ALK1ecd treatment on HepG2 cell growth. A, B and C. HepG2 cells were incubated for 1
hour with A. dorsomorphin (1 mM, Dm), B. LDN193189 (100 nM) or C. ALK1ecd (16 fold molar excess, F.M.E.) and 2/+ BMP9 (5 ng/ml) in 0.1% FBS
media. Western blots were performed with antibodies that recognize P-Smad1,5,8 and Smad1 as loading control. A representative experiment of 2 is
shown in each case. D. HepG2 cells were incubated as in A and counted at day 4. Data from 2 independent experiments performed in triplicate
(mean 6 S.E.M.). E. HepG2 cells were incubated as in B and counted at day 4. Data from 3 independent experiments performed in triplicate (mean6
S.E.M.). F. HepG2 cells were incubated as in C and counted at day 4. Data from 3 independent experiments performed in triplicate (mean 6 S.E.M.).
G. HepG2 cells were incubated without (C) or with dorsomorphin (Dm, 1 mM), LDN193189 (100 nM) or ALK1ecd (16 F.M.E) in 0.1% FBS media and
counted at day 4. Data from at least 3 independent experiments performed in triplicate, displayed as percentage of C0 samples (untreated cells,
day = 0) (mean 6 S.E.M). H. THLE3 cells were incubated with ALK1ecd (16 F.M.E) in 0.1% FBS media and counted at day 4. Data from 2 independent
experiments performed in triplicate, displayed as percentage of C0 (untreated cells, day = 0). Statistical analysis was carried out using paired t-test and
data were compared to untreated samples, * = P,0.05, ** = P,0. 01, *** = P,0.001 or as indicated. n.s. = not significant.
doi:10.1371/journal.pone.0069535.g003
Protumorigenic Role of BMP9 in HCC Cells
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e69535
4. BMP9 Increases Proliferation and Impairs Low Serum
Triggered Apoptosis in HepG2 Cells
So far our data clearly demonstrated that exogenously added,
serum derived and autocrine derived BMP9 increases cell growth
in HepG2 cells. Both proliferative and anti-apoptotic properties
have been described for BMP signaling, and indeed BMP9 has
been shown to increase proliferation in a variety of cell types
[27,34,37], including liver cells [30]. In agreement with previous
reports we found that BMP9 increased cell proliferation, measured
by the [3H]-thymidine incorporation assay (figure 5A). We further
confirmed these data by performing flow cytometric analysis of
DNA content in HepG2 cells treated or not with BMP9 for 24
hours in 0.1% FBS media. Our data show that upon BMP9
treatment an increase in the percentage of HepG2 cells in S/G2/
M phases is observed concomitantly with a decrease in the
percentage of cells in G0/G1 phases. Indeed, cells incubated in
presence of serum (10%) and BMP9 treated cells (0.1% FBS)
present similar percentages of cells in each cell cycle phase,
indicating that BMP9-promoted cell proliferation is comparable to
that observed in cells incubated with 10% FBS (figure 5B). It is
noteworthy that at 24 hours of treatment, the percentage of
hypodiploid cells (sub-G1 peak) was very low and similar in all
conditions assayed (percentage of subG1 cells #1%) indicating the
absence of an apoptotic process in this early time point. It has been
previously described that serum starvation triggers an apoptotic
death in HepG2 cells [38,39], effect that was also observed in our
assay conditions (0.1% FBS). Indeed, after 4 days in low serum
media an important increase in apoptotic cells was observed,
measured by analysis of hypodiploid cells, by phosphatidylserine
exposure on the outer leaflet of the plasma membrane and by
quantification of apoptotic nuclei (figure 5C, 5D and 5E).
Strikingly, BMP9 treatment efficiently abolished the apoptotic cell
death in these conditions. In this line of evidence, we also found
that BMP9 partially rescued cell death induced by other apoptotic
stimuli such as TNF-a in HepG2 cells (figure S6 in File S1).
Collectively, data presented here indicate that BMP9 has a dual
role, both promoting a marked proliferative response and exerting
an anti-apoptotic function in HepG2 cells, which results in a
robust BMP9 effect on liver cancer cell growth.
5 BMP9 Expression is Increased over Normal Levels in
43% of HCC Human Samples
In order to explore BMP9 expression levels in human HCC
samples, an immunohistochemistry (IHC) analysis on a small
Figure 4. BMP9 production supports HepG2 anchorage dependent and independent cell growth. A. Independent stable cell lines
expressing non-silencing (N.S.) and two different shRNAs targeted against BMP9 were generated by retroviral infection of HepG2 cells. BMP9 mRNA
levels were determined by quantitative RT-PCR and normalized to 18S. Data expressed relative to N.S. cells (assigned an arbitrary value of 1) from 3
different experiments (mean 6 S.E.M). B. Non-silencing (NS), shBMP9#1 and #2 stable HepG2 cell lines were incubated in 0.5% FBS and 2/+ BMP9
(5 ng/ml) and counted at day 6. Data from 6 independent experiments performed in triplicate, displayed as percentage of N.S. untreated cells (mean
6 S.E.M). C. HepG2 cells were plated in soft agar and treated with BMP9 (5 ng/ml) or with dorsomorphin (Dm, 1 mM) for 3 weeks (added twice a
week) and the colony number was counted. Data (n = 4, BMP9; n = 8, Dm) are displayed as percentage of control cells (mean 6 S.E.M). D. Previously
generated non-silencing (N.S.), shBMP9#1 and #2 stable HepG2 cell lines were plated in soft agar and counted after 3 weeks. Data from 4
experiments, displayed as percentage of N.S. cells (mean 6 S.E.M). Statistical analysis was carried out using paired t-test and data were compared to
untreated N.S. or control samples or as indicated, * = P,0.05, ** = P,0. 01, *** = P,0.001.
doi:10.1371/journal.pone.0069535.g004
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commercial liver cancer tissue microarray (TMA) was performed.
The TMA contained 8 non-neoplastic and 35 HCC samples from
cancer patients. As a negative control for BMP9 staining we used
non-epithelial ovarian tumor samples, since we had previously
shown that BMP9 expression is specifically absent in this ovarian
cancer type [27] (figure S7 in File S1). Results presented in figure 6
show that BMP9 expression was detected in non-neoplastic liver
samples (figure 6A and data not shown). These data are in
agreement with previous data in the literature describing that
normal human liver parenchymal cells i.e. hepatocytes and
intrahepatic biliary epithelial cells express BMP9 [22]. When
BMP9 staining was analyzed in HCC samples, we could observe
different degrees in BMP9 expression, ranging from low expres-
sion (figures 6B and 6E) to high expression (figures 6C, 6D and
6F). We then classified HCC samples according to their BMP9
expression as compared to BMP9 expression levels in non-
neoplastic liver specimens as follows: BMP9 expression levels over
normal liver levels, BMP9 expression levels equal or lower than
normal liver (figure 6G). Using this approach, we found that 43%
(15 out of 35 HCC patients) presented increased BMP9 expression
levels as compared with non-neoplastic liver. These results are in
agreement with a recently published work that found that 39% of
human HCC samples analyzed presented a moderate to strong
BMP9 staining. Expression levels of BMP9 were positively
correlated with invasion [23]. The number of samples contained
in our TMA and their associated clinical data did not allow us to
establish further clinical correlations. It would be most interesting
to extend these observations with a more numerous TMA with
matching clinical parameters. Nevertheless, these data suggest that
BMP9 protein expression may be dysregulated during hepatocar-
Figure 5. BMP9 increases proliferation and impairs low serum triggered apoptosis in HepG2 cells. A. DNA synthesis as determined by
thymidine incorporation in HepG2 cells cultured for 24 hours in the absence or presence of BMP9 (5 ng/ml). Data are mean6 S.E.M. of 4 independent
experiments and are displayed as percentage of untreated cells. B. HepG2 cells were incubated with or without BMP9 (5 ng/ml) in 0.1% FBS media or
in the presence on 10% FBS media for 24 hours and then nuclear DNA content was analyzed by flow cytometry. Percentages of cells corresponding to
the different cell cycle phases are shown. Data from 3 independent experiments performed in triplicate (mean 6 S.E.M.). Statistical analysis was
carried out using the paired t-test and data were compared to untreated samples (0.1% FBS), * = P,0.05, ** = P,0. 01, *** = P,0.001. C, D, E. HepG2
cells were treated as in B for 4 days. C–D. Cells were trypsinized and C. Nuclear DNA content was analyzed by flow cytometry. Percentages of
hypodiploid (apoptotic) cells are shown. Data from 3 independent experiments performed in triplicate (mean 6 S.E.M.). D. Cells were incubated with
annexin V and PI. Subsequently, fluorescence intensity was measured in a FACScan flow cytometer and the percentage of annexin V positive/PI
negative cells was calculated. Data from 3 independent experiments performed in triplicate (mean 6 S.E.M.). E. Apoptotic nuclei were visualized and
counted after PI staining under a fluorescence microscope. A minimum of 1000 nuclei was counted per condition. Data from 2 independent
experiments performed in triplicate (mean 6 S.E.M.). Statistical analysis was carried out using the paired t-test and data were compared to 10% FBS
media treated samples or as indicated, * = P,0.05, ** = P,0. 01, *** = P,0.001.
doi:10.1371/journal.pone.0069535.g005
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cinogenesis and that elevated BMP9 production together with a
differential response to this factor may constitute a strategy to
increase the tumor cell proliferation and survival.
Discussion
BMP9 regulates different cellular processes in a variety of cell
types, and in particular, the BMP9/ALK1 axis has been unveiled
as a major regulator of endothelial cell biology [35,40,41,42]. An
important role for BMP signaling in liver development is well
established. However, only in the past few years the involvement
of BMP signaling in adult liver homeostasis has been revealed [15].
In particular, the role of BMP9 in liver cells is only partially
understood. In this regard, just recently has been demonstrated
that BMP9 induces EMT that results in an increased migration of
HCC cells [23]. Here, we have investigated the relevance of BMP9
in liver tumor cell biology and have found that BMP9 has dual
pro-tumorigenic functions in HCC cells promoting both anchor-
age dependent and independent growth and survival.
The proliferative effect of BMP9 was only observed in
transformed hepatocytes. Neither the immortalized human adult
hepatocyte THLE3 cell line nor primary mouse adult or
immortalized mouse neonatal hepatocytes did respond to BMP9
in terms of cell growth. Differences at receptor expression level
could be the reason behind the different BMP9 response between
non-transformed and transformed hepatic cells. Although we have
not determined which type I receptor, ALK1 or ALK2, is
mediating BMP9 responses several evidences point towards
ALK2. Firstly, ALK1 expression is largely thought to be restricted
to endothelial cells [43], although some ovarian cancer cells [27],
chondrocytes [44] and interestingly, hepatic stellate cells [45] do
express it. ALK1 mRNA was not detected by RT-PCR in HepG2
cells [23] (Herrera and Inman, unpublished data). Importantly,
HepG2 cells do express ALK2 [23,24], and data from our
laboratory and others indicate that BMP9 is able to bind ALK2
receptor in non-endothelial cells, such as myoblasts, breast tumor
cells and ovarian surface epithelial and ovarian cancer cells
[27,35]. It is well established that Dm and LDN193189 are type I
BMP receptor (ALK2, ALK3 and ALK6) inhibitors, but no data
are available in the literature regarding their potential inhibitory
effect on ALK1. Data presented in this work indicate that both
Dm and LDN193189 completely block BMP9-triggered signaling
and proliferative effect in HepG2 cells, further suggesting ALK2
involvement in those events. Nevertheless, a detailed analysis of
BMP receptors and also co-receptor expression in normal and
transformed hepatocytes is required to fully clarify this point.
It is noteworthy that the differential response to BMP9 in
immortalized human hepatocytes and HepG2 cells is independent
of the BMP9 source. Our data indicate that exogenously added,
serum-derived and autocrine BMP9 promotes cell growth in
HepG2 cells but not in immortalized human hepatocytes. Both
pharmacological inhibition of BMPs (dorsomorphin and
LDN193189) and incubation of cells with ALK1ecd ligand trap
in low serum conditions decreased HepG2 cell growth, while
ALK1ecd treatment did not have any effect on THLE3 cell
growth. Importantly, these results were confirmed by siRNA and
shRNA-mediated BMP9 silencing, which further demonstrated
that BMP9 knockdown in HepG2 cells decreased both basal
proliferation and anchorage independent growth. Acquisition of
growth factor autocrine loops have been described in HCC cells
whose function is to enhance or support their tumorigenic
properties. Thus, ligands of the EGF family and their receptors
have been shown to play an active role not only in cell growth, but
also in the regulation of cell motility and invasion
[46,47,48,49,50]. HGF mRNA is not found in normal hepato-
cytes, but expressed in a high percentage of HCC, and in fact,
in vivo data support a role for the autocrine HGF/Met axis in
tumor promotion [51,52,53]. Along these lines, TGF-b inhibition
by different means impairs HCC cell proliferation and invasion,
suggesting a pro-tumorigenic role for autocrine TGF-b in HCC
cells [54]. Different cancer types have been described to present
BMP ligand autocrine loops, including BMP9 [12,27]. Important-
ly, HCC cells overexpress BMP4 and BMP6, which are required
for migration, invasion and anchorage independent growth
[17,18,20]. In line with these evidences, our in vitro and in vivo
data suggest that BMP9 production is increased in at least a subset
of HCC and this autocrine loop enhances cell growth. How cancer
cells acquire autocrine growth factors production is not completely
understood. In the case of BMP9, our IHC data and previous
reports indicate that healthy liver already produces BMP9 [22,29],
therefore, we hypothesize that HCC cells rather than acquire an
autocrine production of BMP9 itself, gain the capacity of
responding to BMP9 in terms of proliferation and cell survival.
Importantly, our data clearly show that BMP9 promotes cell
growth at the same level of well-established liver growth factors
such as EGF, IGF1 or insulin and is also involved in anchorage
independent growth in HepG2 cells. BMP9 is not only a strong
mitogen but it has also an important survival effect against low-
serum-induced apoptosis. Thus, consistent with previous results
[38,39] serum deprivation triggers an apoptotic cell death in
HepG2 cells that is significantly diminished when cells are treated
with BMP9. Our data also reveal that BMP9 could have a survival
effect in cell death induced by other apoptotic stimuli such as
TNF-a. Taken together, these data constitute the first evidence for
a role of BMP9 as an anti-apoptotic factor. The molecular
mechanisms underlying such effect are the current focus of our
studies.
In conclusion, awaiting further investigation to explore BMP9
function in non-transformed hepatocytes, we provide evidence to
propose BMP9 as a regulator of HCC cell growth, by promoting
proliferation and survival. Our data adds to the growing body of
evidence that suggest the BMPs may have pro-tumorigenic roles in
HCC and may be considered as potential therapeutic targets in
HCC therapy. In this regard, several drug companies are
developing ALK1 inhibitors on the basis of its antiangiogenic
properties [43] and clinical trials to assess ALK1 inhibitors effects
in advanced solid tumors have been launched. Giving the fact that
HCC is a hypervascularized tumor [55], and that ALK1 is highly
expressed in liver tumor blood vessels [56] HCC may be a good
candidate for ALK1 inhibition therapeutic strategy. Furthermore,
results presented in this work showing pro-tumorigenic functions
for BMP9 in HCC cells acting to promote both anchorage
dependent and independent growth and survival provide further
evidences for the use of ALK1-fusion protein in HCC treatment
considering that BMP9 withdrawal achieved by these drugs may
target the liver cancer cell itself.
Figure 6. BMP9 expression is increased over normal levels in 43% of human HCC samples. Sections of formalin fixed paraffin embedded
human liver tissues were stained with BMP9 antibody and counterstained with haematoxylin. Representative images of A. non neoplastic human
liver; B and C. human HCC japanese stage II; D, E, F. HCC japanese stage III. Scale bars represent 100 mm. G. Table summarizing BMP9 IHC of a
human liver cancer TMA. Staining was scored as stronger, equal and lower BMP9 staining than non-neoplastic tissue.
doi:10.1371/journal.pone.0069535.g006
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